# Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

> **NCT01623596** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 881 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Disease Modifying therapy

## Key facts

- **NCT ID:** NCT01623596
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-08
- **Primary completion:** 2015-07-13
- **Final completion:** 2015-07-13
- **Target enrollment:** 881 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623596, "Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01623596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*